Here's Why Voyager Therapeutics Gained as Much as 24.9% Today
Shares of clinical-stage biopharma Voyager Therapeutics (NASDAQ: VYGR) popped nearly 25% today after the company announced positive results for a phase 1b trial investigating the potential of its lead drug candidate to treat advanced Parkinson's disease. The early-stage gene therapy, VY-AADC01, demonstrated dose-dependent responses for several metrics including measures of daily activities, Parkinson's disease rating scales, and patient diaries.
Management noted that the results will allow the company to initiate a pivotal phase 2/3 trial later this year and to dose the first patient in the first half of 2018. That was all the stock needed to find momentum after struggling for much of the last two years. As of 11:59 a.m. EDT, the stock had settled to a 16.7% gain.
Image source: Getty Images.
Source: Fool.com
Voyager Therapeutics Inc Stock
Our community is currently high on Voyager Therapeutics Inc with 3 Buy predictions and 0 Sell predictions.
Based on the current price of 7.6 € the target price of 16 € shows a potential of 110.66% for Voyager Therapeutics Inc which would more than double the current price.
